Study of TAK-816 in Healthy Infants

Takeda416 enrolled

Overview

The purpose of this study is to evaluate the efficacy (immunogenicity) of TAK-816 when administered to healthy Japanese infants as multiple subcutaneous doses.

Haemophilus Influenzae type b (Hib) is one of the major causes of infectious meningitis in children, and can also cause sepsis, cellulitis, arthritis, epiglottitis, pneumonia and myelitis. TAK-816 is a conjugated Hib vaccine being tested in healthy infants aged 3-6 months at the time of the first dose. The objective of this study is to evaluate the efficacy (immunogenicity) and safety of TAK-816 (10 ϻg/0.5 mL) in comparison with ActHIB (Haemophilus b Conjugate Vaccine) as a control. In addition, the efficacy (immunogenicity) and safety of Absorbed Diphtheria-Purified Pertussis-Tetanus Combined (DPT-TAKEDA) vaccine when TAK-816 and DPT vaccine are administered concomitantly will also be investigated. For the Primary Immunization Phase of this study: three doses of TAK-816 or ActHIB 10 µg/0.5 mL and DPT-TAKEDA 0.5 mL will be administered at 4-week intervals over 8 weeks (Visit 1, 2, 3). At4 weeks after the third dose, a follow-up observation and evaluation will be made (Visit 4). For the Booster Vaccination Phase of this study: a single dose of TAK-816 or ActHIB 10 µg/0.5 mL and DPT-TAKEDA 0.5 mL will be given at 52 weeks after the third dose (Visit 5). At 4 weeks after the fourth dose, a follow-up observation and evaluation will be made (Visit 6).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

416

Conditions

Immunization

Interventions

TAK-816+ DPT-TAKEDABIOLOGICAL

TAK-816 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.

ActHIB+ DPT-TAKEDABIOLOGICAL

ActHIB 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.

Eligibility

Sex: ALLMin age: 3 MonthsMax age: 6 MonthsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female infants aged ≥3 and \<7 months (excluding hospitalized infants). 2. Infants whose legal acceptable representatives have given informed consent to the study prior to enrollment. 3. Infants whose parents or legal guardians have agreed to cooperate with the investigator during the study period. Exclusion Criteria: 1. Any serious acute illness. 2. Any underlying cardiovascular, renal, hepatic, or hematologic disease, and/or developmental disorder. 3. History of possible Haemophilus influenzae type b (Hib) infection. 4. History of possible pertussis, diphtheria or tetanus infection. 5. Previously diagnosed immunodeficiency. 6. A documented history of anaphylaxis to any ingredient of the investigational products (TAK-816, ActHIB or DPT-TAKEDA). 7. A history of convulsions. 8. Previous administration of another Hib vaccine. 9. Previous administration of any other vaccine containing any of the components of polio, diphtheria, pertussis, or tetanus. 10. Treatment with any live vaccine during the 27 days before the first dose of TAK-816 or with any inactivated vaccine during the 6 days before dosing.

Locations (22)

Unnamed facility

Isumi, Chiba, Japan

Unnamed facility

Urayasu-shi, Chiba, Japan

Unnamed facility

Fukuoka, Fukuoka, Japan

Outcomes

Primary Outcomes

Proportion of participants with an anti-polyribosylribitol phosphate (PRP) titer ≥1 ϻg/mL

Time frame: 4 weeks after the third dose (Visit 4)

Secondary Outcomes

Proportion of participants with an anti-polyribosylribitol phosphate (PRP) titer ≥0.15 ϻg/mL

Time frame: 4 weeks after the third dose (Visit 4)

Proportion of participants with an anti-PRP geometric mean titers (GMT)

Time frame: 4 weeks after the third dose (Visit 4)

Proportion of participants with an anti-PRP titer ≥1 ϻg/mL

Time frame: 4 weeks after the single booster dose. (Visit 6)

Proportion of participants with an anti-PRP titer ≥0.15 ϻg/mL

Time frame: 4 weeks after the single booster dose. (Visit 6)

Proportion of participants with an anti-PRP GMT

Time frame: 4 weeks after the single booster dose. (Visit 6)

Proportion of participants with an anti-diphtheria toxoid titer ≥0.1 IU/mL

Time frame: 4 weeks after the third dose (Visit 4)

Proportion of participants with an anti-diphtheria toxoid GMT

Time frame: 4 weeks after the third dose (Visit 4)

Proportion of participants with an anti-diphtheria toxoid titer ≥0.1 IU/mL

Time frame: 4 weeks after the single booster dose (Visit 6)

Proportion of participants with an anti-diphtheria toxoid GMT

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.